DISEASE INDICATIONS: Primary hyperoxaluria type 1 (PH1)
MANUFACTURER: Alnylam Pharmaceuticals
USAGE: Subcutaneous
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Oxlumo (lumasiran) is a prescription medicine used to treat primary hyperoxaluria type 1 (PH1) in children and adults. PH1 is a rare genetic disorder that causes the body to produce too much of a substance called oxalate. Oxaluria can cause kidney stones, damage to the kidneys and other organs, and even death.
